Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial

被引:10
|
作者
Bertrand, Olivier F. [1 ]
Rodes-Cabau, Josep [1 ]
Larose, Eric [1 ]
Nguyen, Can Manh [1 ]
Dery, Jean-Pierre [1 ]
Proulx, Guy [1 ]
Roy, Louis [1 ]
Poirier, Paul [1 ]
Costerousse, Olivier [1 ]
De Larochelliere, Robert [1 ]
机构
[1] Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol, Intervent Cardiol Labs, Ste Foy, PQ G1V 4G5, Canada
关键词
Abciximab; Intracoronary; Stent; Platelets; Transradial; ACUTE MYOCARDIAL-INFARCTION; PLATELET-RICH CLOTS; UNSTABLE ANGINA; ANGIOPLASTY; BOLUS; EPTIFIBATIDE; INFUSION; PCI;
D O I
10.1016/j.ijcard.2008.04.073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In the EASY trial, we have shown the clinical equivalence between abciximab bolus-only and abciximab bolus followed by 12-h infusion in a wide spectrum of patients after percutaneous coronary intervention (PCI). Some reports have suggested better outcomes following intracoronary (IC) abciximab administration compared to intravenous (IV) delivery. We sought to compare cardiac biomarkers release and early and late clinical outcomes after IC or IV abciximab bolus delivery. Methods: From 1005 patients randomized in the EASY trial and undergoing transradial coronary stent implantation, 208 received IC abciximab bolus and 797 received IV abciximab bolus. Route of administration was left to operators' discretion. Creatine Kinase-MB, and Troponin-T (Tn-T) were obtained immediately prior to angiography, 4-6 h after PCI and the next day. MACE (death, MI, TVR) rate was evaluated at 30 days, 6 months and 12 months. Results: There were more patients with acute coronary syndrome (75% vs 64%, P=0.004) and previous MI (53% vs 42%, P=0.005) in the IC group and more patients with >= 3 dilated sites in the IV group (2% IC vs 7% IV, P=0.03). After PCI, the extent of Tn-T and CK-MB release remained comparable in both groups. The MACE rate was 2% in both groups at 30 days, 9% in IC bolus vs 5% in IV bolus (P=0.04) at 6 months and 10% in IC bolus vs 9% in IV bolus (P=0.50) at 12 months. By multivariate analysis, IC abciximab bolus was not associated with better outcomes at 12 months compared to IV bolus (HR 1.07, 95% CI 0.82-1.35, P=0.62). Conclusion: Compared to IV abciximab administration, IC abciximab was not associated with less cardiac biomarkers release or better clinical outcomes after uncomplicated transradial PCI. Further studies are required in clinical scenarios including patients with higher thrombotic burden and/or occluded vessels as in primary and rescue PCI. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 50 条
  • [1] Improved Clinical Outcomes with Intracoronary Compared to Intravenous Abciximab in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
    Hansen, Peter Rus
    Iversen, Allan
    Abdulla, Jawdat
    JOURNAL OF INVASIVE CARDIOLOGY, 2010, 22 (06) : 278 - 282
  • [2] Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction
    Eitel, Ingo
    Desch, Steffen
    Schindler, Kathrin
    Fuernau, Georg
    Schuler, Gerhard
    Thiele, Holger
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 153 (01) : 21 - 25
  • [3] Intracoronary Versus Intravenous Administration of Abciximab in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration The Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial
    Gu, Youlan L.
    Kampinga, Marthe A.
    Wieringa, Wouter G.
    Fokkema, Marieke L.
    Nijsten, Maarten W.
    Hillege, Hans L.
    van den Heuvel, Ad F. M.
    Tan, Eng-Shiong
    Pundziute, Gabija
    van der Werf, Rik
    Guyomi, Siyrous Hoseyni
    van der Horst, Iwan C. C.
    Zijlstra, Felix
    de Smet, Bart J. G. L.
    CIRCULATION, 2010, 122 (25) : 2709 - 2717
  • [4] Intracoronary Compared to Intravenous Abciximab and High-Dose Bolus Compared to Standard Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Transradial Primary Percutaneous Coronary Intervention: a Two-by-Two Factorial Placebo-Controlled Randomized Study
    Bertrand, Olivier F.
    Rodes-Cabau, Josep
    Larose, Eric
    Rinfret, Stephane
    Gaudreault, Valerie
    Proulx, Guy
    Barbeau, Gerald
    Dery, Jean-Pierre
    Gleeton, Onil
    Manh-Nguyen, Can
    Noel, Bernard
    Roy, Louis
    Costerousse, Olivier
    De Larochelliere, Robert
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (11) : 1520 - 1527
  • [5] Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention
    Bedjaoui, Ali
    Allal, Karima
    Lounes, Mohamed Sofiane
    Belhadi, Chams Eddine
    Mekarnia, Abdelmoumen
    Sediki, Saber
    Kara, Maamar
    Azaza, Adel
    Monsuez, Jean-Jacques
    Benkhedda, Salim
    CARDIOVASCULAR JOURNAL OF AFRICA, 2019, 30 (01) : 45 - 51
  • [6] Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention - The randomized leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial
    Thiele, Holger
    Schindler, Kathrin
    Friedenberger, Josef
    Eitel, Ingo
    Fuernau, Georg
    Grebe, Eigk
    Erbs, Sandra
    Linke, Axel
    Moebius-Winkler, Sven
    Kivelitz, Dietmar
    Schuler, Gerhard
    CIRCULATION, 2008, 118 (01) : 49 - 57
  • [7] Comparison Between Intracoronary and Intravenous Eptifibatide and Intracoronary Reteplase in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial
    Nikfarjam, Salman
    Zadkamali, Mostafa
    Salari, Arsalan
    Shakiba, Maryam
    Hoseinie, Mahboubeh Janesar
    Mirbolouk, Fardin
    IRANIAN HEART JOURNAL, 2022, 23 (01):
  • [8] Similar anti-inflammatory effects of intracoronary and intravenous Abciximab during primary percutaneous coronary intervention: a randomized study
    Secco, Gioel Gabrio
    Sansa, Mara
    Rognoni, Andrea
    Parisi, Rosario
    Fattori, Rossella
    Rossi, Lidia
    Lazzero, Maurizio
    Rolla, Roberta
    Bellomo, Giorgio
    Bongo, Angelo Sante
    Agostoni, Pierfrancesco
    Di Mario, Carlo
    Lupi, Alessandro
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2015, 16 (03) : 189 - 196
  • [9] Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Piccolo, Raffaele
    Eitel, Ingo
    Galasso, Gennaro
    Iversen, Allan Zeeberg
    Gu, Youlan L.
    Dominguez-Rodriguez, Alberto
    de Smet, Bart J. G. L.
    Mahmoud, Karim D.
    Abreu-Gonzalez, Pedro
    Thiele, Holger
    Piscione, Federico
    VASCULAR PHARMACOLOGY, 2015, 73 : 32 - 37
  • [10] Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials
    Navarese, Eliano Pio
    Kozinski, Marek
    Obonska, Karolina
    Margheri, Massimo
    Gurbel, Paul Alfred
    Kubica, Jacek
    De Luca, Giuseppe
    PLATELETS, 2012, 23 (04) : 274 - 281